Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22062834 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL20028722 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL19165618 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL25907251 | 0.80 | CHRNB4 (0.43) | CHRNB4CHRNA3 | |
| SCHEMBL23979788 | 0.78 | CHRNB4 (0.44) | CHRNB4CHRNA3 | |
| SCHEMBL23023341 | 0.78 | CYP1A2 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL23979781 | 0.78 | CHRNB4 (0.44) | CHRNB4CHRNA3 | |
| SCHEMBL24730512 | 0.78 | CYP1A2 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL23979774 | 0.78 | CHRNB4 (0.44) | CHRNB4CHRNA3 | |
| SCHEMBL25808898 | 0.78 | CYP1A2 (0.47) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CHRNB4 4183/4885CHRNA3 4195/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CHRNB4 4183/4885CHRNA3 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.